Publication:
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Issued Date

2021-08-05

Resource Type

Article

ISSN

10974172
00928674

DOI

10.1016/j.cell.2021.06.020

Other identifier(s)

2-s2.0-85109642517

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Cell. Vol.184, No.16 (2021), 4220-4236.e13

Suggested Citation

Chang Liu, Helen M. Ginn, Wanwisa Dejnirattisai, Piyada Supasa, Beibei Wang, Aekkachai Tuekprakhon, Rungtiwa Nutalai, Daming Zhou, Alexander J. Mentzer, Yuguang Zhao, Helen M.E. Duyvesteyn, César López-Camacho, Jose Slon-Campos, Thomas S. Walter, Donal Skelly, Sile Ann Johnson, Thomas G. Ritter, Chris Mason, Sue Ann Costa Clemens, Felipe Gomes Naveca, Valdinete Nascimento, Fernanda Nascimento, Cristiano Fernandes da Costa, Paola Cristina Resende, Alex Pauvolid-Correa, Marilda M. Siqueira, Christina Dold, Nigel Temperton, Tao Dong, Andrew J. Pollard, Julian C. Knight, Derrick Crook, Teresa Lambe, Elizabeth Clutterbuck, Sagida Bibi, Amy Flaxman, Mustapha Bittaye, Sandra Belij-Rammerstorfer, Sarah C. Gilbert, Tariq Malik, Miles W. Carroll, Paul Klenerman, Eleanor Barnes, Susanna J. Dunachie, Vicky Baillie, Natali Serafin, Zanele Ditse, Kelly Da Silva, Neil G. Paterson, Mark A. Williams, David R. Hall, Shabir Madhi, Marta C. Nunes, Philip Goulder, Elizabeth E. Fry, Juthathip Mongkolsapaya, Jingshan Ren, David I. Stuart, Gavin R. Screaton Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. Vol.184, No.16 (2021), 4220-4236.e13. doi:10.1016/j.cell.2021.06.020 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/76068

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Author(s)

Chang Liu
 Helen M. Ginn
 Wanwisa Dejnirattisai
 Piyada Supasa
 Beibei Wang
 Aekkachai Tuekprakhon
 Rungtiwa Nutalai
 Daming Zhou
 Alexander J. Mentzer
 Yuguang Zhao
 Helen M.E. Duyvesteyn
 César López-Camacho
 Jose Slon-Campos
 Thomas S. Walter
 Donal Skelly
 Sile Ann Johnson
 Thomas G. Ritter
 Chris Mason
 Sue Ann Costa Clemens
 Felipe Gomes Naveca
 Valdinete Nascimento
 Fernanda Nascimento
 Cristiano Fernandes da Costa
 Paola Cristina Resende
 Alex Pauvolid-Correa
 Marilda M. Siqueira
 Christina Dold
 Nigel Temperton
 Tao Dong
 Andrew J. Pollard
 Julian C. Knight
 Derrick Crook
 Teresa Lambe
 Elizabeth Clutterbuck
 Sagida Bibi
 Amy Flaxman
 Mustapha Bittaye
 Sandra Belij-Rammerstorfer
 Sarah C. Gilbert
 Tariq Malik
 Miles W. Carroll
 Paul Klenerman
 Eleanor Barnes
 Susanna J. Dunachie
 Vicky Baillie
 Natali Serafin
 Zanele Ditse
 Kelly Da Silva
 Neil G. Paterson
 Mark A. Williams
 David R. Hall
 Shabir Madhi
 Marta C. Nunes
 Philip Goulder
 Elizabeth E. Fry
 Juthathip Mongkolsapaya
 Jingshan Ren
 David I. Stuart
 Gavin R. Screaton

Other Contributor(s)

Siriraj Hospital
 Mahidol Oxford Tropical Medicine Research Unit
 NIHR Oxford Biomedical Research Centre
 Oxford University Hospitals NHS Foundation Trust
 Texas A&M College of Veterinary Medicine & Biomedical Sciences
 Public Health England
 Diamond Light Source
 University of the Witwatersrand Faculty of Health Sciences
 University of Oxford
 Fundacao Oswaldo Cruz
 Fiocruz Amazônia
 School of Pathology
 University of Kent
 Nuffield Department of Medicine
 Università degli Studi di Siena
 University of Oxford Medical Sciences Division
 Oxford House
 Fundação de Vigilância em Saúde do Amazonas

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations.

Keyword(s)

Biochemistry, Genetics and Molecular Biology

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/76068

Collections

Scopus 2021